Skip to content

Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepotectomy with narrow margin

Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepotectomy with narrow margin

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002717
Enrollment
Unknown
Registered
2012-11-23
Start date
2007-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

adjuvant RT group:adjuvant RT

Sponsors

cancer institute & hospital. Chinese academy of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 75 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria can be categorized as follows: (1) centrally located HCC with no preoperative radiotherapy; (2) resectable lesion appraised by our surgery panel, with possibility of completely removing tumors and retaining a sufficient residual liver to maintain liver function; (3) age between 17 and 75 years; (4) compensated cirrhosis or no cirrhosis; (5) Child–Pugh liver function class A; (6) Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Patients who had received previous trans-arterial chemoembolization were eligible for enrolment in the study. The therapy must have been stopped at least 4 weeks before study entry.

Exclusion criteria

Exclusion criteria: We excluded such patients as: (1) presence of distant metastasis; (2) resection margin > 1cm; (3) palliative resection with tumor residual; (4) non-HCC confirmed by postoperative pathology. Eligible patients for adjuvant radiotherapy arm were requested to recover within 6 weeks after surgery and have adequate hepatic and renal function, a ECOG PS of 0 or 1, no fever and no active sepsis so as to tolerate adjuvant radiotherapy.

Design outcomes

Primary

MeasureTime frame
overall survival;

Secondary

MeasureTime frame
recurrent-free survival;

Countries

China

Contacts

Public ContactWu jianxiong
dr_wujianxiong@yahoo.com.cn+86 15811140261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026